PUBLICATION

CPhI

AUTHORS

JP Stevenson, Alex Heeley

DOWNLOAD THE FULL PDF

Turkey Pharma 2014 CPhI Pharmaceuticals Insights

Pharma & Life Sciences

Turkey

May 03, 2014

Estimated to reach a value of $36 billion by 2023, Turkey’s pharmaceuticals manufacturing industry shows strong growth potential. Government support, high technological standards, and logistical advantages make Turkey an excellent place to manufacture and export pharmaceuticals. If the public and private sectors can collaborate to improve practices and profit margins, the country will become a global pharmaceuticals powerhouse.

RELATED INTERVIEWS MORE INTERVIEWS

Bassil Dahiyat

PRESIDENT AND CEO, XENCOR

Powered by its XmAb antibody engineering platform, Xencor is developing a broad pipeline of drug candidates that are optimized to treat autoimmune disorders, cancer, asthma and allergic diseases.

United States

Pharma & Life Sciences

Peter DeYoung

CEO, PIRAMAL

Piramal Pharma updates GBR in its recent developments and prospects.

Pharma & Life Sciences

India

Barbara Weber

CEO, TANGO THERAPEUTICS

Tango Therapeutics is targeting unaddressed disease mechanisms in cancer to develop transformational new drugs for patients.

United States

Pharma & Life Sciences

David Cory

CEO, EIGER BIOPHARMACEUTICALS

Founded in 2008, Eiger BioPharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing targeted therapies for rare diseases.

United States

Pharma & Life Sciences

Finding Funding: The Diversification of the Biotech Financing Landscape

United States Biopharmaceuticals 2018

The methods of financing biotech R&D are evolving as large pharma companies and governments look to small biotech start-ups to provide the next generation of medicines.

Pharma & Life Sciences

Turkey

A West-Meets-East Of The Pharma Industry

Turkey Pharmaceuticals & Biopharmaceuticals 2020

Portrait of the Turkey Pharmaceuticals industry.

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

MORE PREVIOUSLY PUBLISHED